To reduce the risk of hip and vertebral fractures in women with osteoporosis, physicians should treat them with the bisphosphonates risedronate, alendronate, or zoledronic acid, or alternatively with the biologic agent denosumab. This strong recommendation appears in revised guidelines from the American College of Physicians (ACP) for the prevention of fractures in men and women… Read more »
Osteoporosis in the News
NOF Response to the Newly Published “Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update from the American College of Physicians” (ACP) »
On Monday, May 8th, the American College of Physicians (ACP) released its updated guidelines for treatment of men and women with low bone density or osteoporosis. The National Osteoporosis Foundation (NOF) applauds the ACP for recognizing the need to update its previous guidelines from 2008 and emphasizing the importance of treatment for osteoporosis and the… Read more »
FDA Approves Radius Health’s TYMLOS™ (abaloparatide) »
Apr 28, 2017 FDA Approves Radius Health’s TYMLOS™ (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture TYMLOS is the first new anabolic (bone building) agent for postmenopausal women with osteoporosis in the United States in nearly 15 years US Commercial Launch in May Approval Based… Read more »
Calcium Supplements and the Heart: Clearing Up the Confusion »
A video interview was recorded with Dr. JoAnn Manson, professor of medicine at Harvard Medical School and Brigham and Women’s Hospital. She spoke about calcium supplements and the heart which is a subject that has been filled with mixed messages and prone to confusion over the past several years. Watch the recording here.
The NOF’s Methods and Processes for Developing Position Statements »
The National Osteoporosis Foundation frequently publishes position statements for the benefit of educating healthcare professionals and the general public on a particular issue and/or concern related to preventing osteoporosis and/or promoting strong bones throughout the lifespan. This manuscript represents the official methods and processes adopted by the NOF Board of Trustees for the purpose developing… Read more »
NOF Response to Report in the Journal of the American Heart Association that Calcium Supplements May Damage the Heart »
We have read and reviewed the report on observational research, published Oct. 10 in the Journal of the American Heart Association, which concludes that taking calcium in the form of supplements may raise the risk of atherosclerosis as assessed by calcium deposits in the coronary arteries, although a diet high in calcium-rich foods appears to… Read more »
Fracture-Liaison Service Greatly Improves Postfracture Care »
ATLANTA — The dismal rate at which treatment of osteoporosis is initiated following any fragility fracture in the United States can be dramatically improved with the help of a fracture-liaison service, a demonstration project indicates. “All three sites, including Georgetown University Hospital, where I am, and the University of Pittsburgh Medical Center and Creighton Health… Read more »
Clinical Trial Results Released For ACTIVE Study »
In its August 16, 2016 issue of The Journal of the American Medical Association (JAMA), the phase 3 results of the Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) trial were released. Read this article here! An accompanying editorial can be found here.
CMS Proposes New Fee Schedules for 2017 »
On July 14, 2016, the Centers for Medicare and Medicaid Services (CMS) published the proposed rule for the Hospital Outpatient Prospective Payment System (HOPPS) for 2017. CMS has proposed to cut the reimbursement rate for Axial DXA, CPT 77080 in the hospital setting from the current national average of $100.69 to $63.33. This reimbursement cut will… Read more »
Fearing Drugs’ Rare Side Effects, Millions Take Their Chances With Osteoporosis »
Millions of Americans are missing out on a chance to avoid debilitating fractures from weakened bones, researchers say, because they are terrified of exceedingly rare side effects from drugs that can help them. Last month, the American Society for Bone and Mineral Research, the National Osteoporosis Foundation and the National Bone Health Alliance put out… Read more »